← All candidates
25 insider filings on record.
30 filings on record.
XENEXenon Pharmaceuticals Inc.
NasdaqGM · Healthcare · $5.45B
$56.28
-3.28% · Sep 15
25 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 12 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$5.45B
Float
90.9M
94% public
Short % float
Pro
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
20 more transactions on Pro →Context
Wall St
$80.56 avg target
+43.1% vs today · 19 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$1.17 act+$0.03
Q4 '25−$1.31 act−$0.10
Q3 '25−$1.15 act+$0.01
Q2 '25−$1.07 act−$0.08
Coverage
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's WhyZacks · 06-23Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation EstimateSimply Wall St. · 06-11JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)Insider Monkey · 05-23What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA FilingMotley Fool · 05-18
The file stays open
30 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice